Skip to Primary Navigation

Skip to main content

Eli Lilly begins enforcing expanded 340B data compliance

A photo of sign at Eli Lilly's corporate headquarters, reading "Lilly."
Photo: Scott Olson/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The drug maker says data about individual transactions, including patient, provider, service, and payment details, is needed to meet obligations under the Inflation Reduction Act.

A deadline set by pharmaceutical manufacturer Eli Lilly for hospitals to submit claims-level data under the federal 340B Drug Pricing Program has passed, leaving some providers at risk of losing access to discounted drug pricing.

Lilly first announced in January that it would begin enforcing a policy requiring the submission

, , , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience